NSCLC, often the most dreaded of all types of lung cancer, is highly likely to metastasize into the bones and other tissues, making it difficult to detect and treat. NSCLC accounts for 90% of all lung cancer cases. Drugs used in the treatment of NSCLC range from regular regimens to targeted therapies. The drugs are based on simple chemistries to highly advanced complex protein. The market is witnessing strong growth due to high awareness among the population through government initiatives. Moreover, the drugs for NSCLC are given swift approvals by regulatory bodies and grants for research. This has led to new generation of drugs being introduced in the NSCLC market.
The major classes of drugs under NSCLC are angiogenesis inhibitor, EGFR blocker, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitors. The angiogenesis inhibitor segment dominated the market in 2014. High efficacy, targeted therapies, and increasing demand in major geographies such as Europe, the U.S., and Japan are attributed to the dominance of the angiogenesis inhibitor segment in the NSCLC therapeutics market. Zykadia is expected to witness the highest growth rate during the forecast period, followed by Opdivo.
Geographically, the NSCLC market segmented into four major regions: North America, Europe, Asia Pacific (APAC), and ROW. North America dominated the global NSCLC therapeutics market in 2014 due to the presence of modern health care infrastructure and an efficient U.S. government system. However, APAC is anticipated to expand at the fastest CAGR during the forecast period. Factors such as increasing population, greater awareness about NSCLC, and growing number of government projects related to lung, cancer, tobacco, and their respective interventions would boost the growth of the market in APAC during the forecast period.
The NSLCLC therapeutics market exhibits intense competition among existing players. The market is fragmented, characterized by the presence of both generic and branded companies. Major players operating in the NSCLC market are Genentech, Inc. ( a Roche Company), Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc., Novartis AG, AstraZeneca plc, and Celgene Corporation.
1.1. Report Description
1.2. Research Methodology
1.3. Market Segmentation
2. Executive Summary
2.1. Market Snapshot
2.2. Comparative Analysis: Non-Small Cell Lung Cancer Market, by Geography, 2014 & 2023 (Value %)
3. Non-Small Cell Lung Cancer Market Overview
3.2. Treatment Guidelines and Disease Management
3.3. Companion Diagnostics: Overview
3.4. Regulatory Scenario
3.5. Market Dynamics
3.6. Event Impact Analysis, 2013 - 2023
3.7. Market Attractiveness Analysis of Global Non-Small Cell Lung Cancer Market, by Geography, 2014
3.8. Competitive Landscape
3.8.1. Market Share Analysis of Key Players, 2014 (Value %)
4. Market Segmentation – By Drug
4.2. Global Non-Small Cell Lung Cancer Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
4.2.1. Global Angiogenesis Inhibitor Market Revenue, 2013–2023 (US$ Mn) and Analysis
4.2.2. Global EGFR Blockers Market Revenue, 2013–2023 (US$ Mn) and Analysis
4.2.3. Global Kinase Inhibitor Market Revenue, 2013–2023 (US$ Mn) and Analysis
4.2.4. Global Microtubule Stabilizer Market Revenue, 2013–2023 (US$ Mn) and Analysis
4.2.5. Global Folate Antimetabolites Market Revenue, 2013–2023 (US$ Mn) and Analysis
4.2.6. Global PD-1/PD-L1 Inhibitor Market Revenue, 2013–2023 (US$ Mn) and Analysis
5. Pipeline Analysis
5.2. Late Stage (Phase III)
5.2.1. Avelumab - Pfizer, Inc.
5.2.2. MPDL3280A - Roche
5.2.3. MEDI4736 - AstraZeneca
5.2.4. Abemaciclib – Eli Lilly and Company
5.3. Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)
6. Market Segmentation – By Geography
6.2. Global Non-Small Cell Lung Cancer Market Revenue, by Region, 2013–2023 (US$ Mn)
6.3. North America Non-Small Cell Lung Cancer Market Revenue, by Country, 2013–2023 (US$ Mn)
6.3.1. U.S. Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.3.2. Canada Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.4. Europe Non-Small Cell Lung Cancer Market – Revenue, by Country, 2013–2023 (US$ Mn)
6.4.1. U.K. Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.4.2. Germany Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.4.3. Rest of Europe Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.5. Asia Pacific Non-Small Cell Lung Cancer Market Revenue, by Country, 2013–2023 (US$ Mn)
6.5.1. Japan Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.5.2. China Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.5.3. Rest of APAC Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.6. Rest of the World Non-Small Cell Lung Cancer Market Revenue, by Country, 2013–2023 (US$ Mn)
7.1. Recommendation 1: Research and Development Initiatives to Penetrate the Market
7.2. Recommendation 2: Investment in Emerging Economy
8. Company Profiles
8.1. Astra Zeneca PLC
8.2. Boehringer Ingelheim
8.3. Bristol-Myers Squibb
8.4. Celgene Corporation
8.5. GlaxoSmithKline PLC
8.6. Eli Lilly & Co.
8.7. Pfizer, Inc.
8.8. Genentech, Inc. (a Roche company)
8.9. Sun Pharmaceutical Industries Ltd.
Of late, the demand for non-small cell lung cancer (NSCLC) therapeutics has witnessed a significant surge, globally. The robust rise in the number of patients suffering from NSCLC across the world is likely to strengthen this trend considerably in the near future. The market for NSCLC therapeutics presented a global opportunity worth US$4.9 bn in 2014. Analysts project it to rise at a CAGR of 12.10% during the period from 2015 to 2023 and attain a value of US$15.1 bn by the end of the forecast period.
In this research report, the global NSCLC therapeutics market has been studied with a microscopic view. It aims at presenting a detailed market assessment on the basis of its past as well as current performance. The latest trends and growth opportunities within this market have been examined in-depth to determine its future status in this study.
Non-Small Cell Lung Cancer Therapeutics Market: Trends and Opportunities
Being the most common type of lung cancer, NSCLC has a large pool of patients suffering from it. Hitherto, angiogenesis inhibitor has been the most successful therapy for NSCLC. The high demand for Avastin in the U.S. and in several European countries is likely to maintain the position of angiogenesis inhibitor as the key treatment for NSCLC in the years to come.
Folate antimetabolites, EGFR inhibitors, and microtubule stabilizers are also expected to gain momentum in the global market over the next few years. In addition, the approval of late-stage pipeline products, such as necitumumab and onartuzumab, are likely to create new revenue streams for drugmakers in the near future.
Non-small Cell Lung Cancer Therapeutics Market: Geographical Analysis
On the basis of geography, the global market for NSCLC therapeutics has been segmented into Europe, Asia Pacific, North America, and the Rest of the World. Thanks to the presence of a state-of-art healthcare infrastructure, North America has emerged as the leading contributor to this market. With favorable insurance and reimbursement scenario, researchers expect this regional market to remain dominant in the forthcoming years.
On the other hand, Asia Pacific is anticipated to offer the most promising opportunities for growth in the near future. The increasing incidence of NSCLC, coupled with unmet medical needs, is likely to make way for the adoption of NSCLC therapeutics at a higher rate. The rise in government initiatives to increase awareness regarding NSCLC among consumers in this region is also projected to propel the Asia Pacific market for NSCLC therapeutics substantially over the next few years.
Companies Mentioned in the Research Report
Owing to the presence of a large pool of players, the global market for non-small cell lung cancer therapeutics demonstrates a highly competitive and fragmented landscape. Genentech Inc., GlaxoSmithKline PLC, Pfizer Inc., Astra Zeneca PLC, Celgene Corp., Eli Lilly & Co., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., and Bristol-Myers Squibb are some of the key players in this market across the world.
Key Segments of Non-Small Cell Lung Cancer Therapeutics Market
By Drug Class
- Angiogenesis Inhibitor
- Avastin (bevacizumab)
- Cyramza (Ramucirumab)
- Epidermal Growth Factor Receptor Blocker
- Tarceva (erlotinib)
- Gilotrif (afatinib)
- Iressa (gefitinib)
- Kinase Inhibitor
- Xalkori (crizotinib)
- Zykadia (ceritinib)
- Microtubule Stabilizer
- Abraxane (paclitaxel protein bound)
- Folate Antimetabolites
- Alimta (pemetrexed)
- PD-1/ PD-L1 Inhibitor
- Opdivo (nivolumab)
- Keytruda (pembrolizumab)
- Early Stage (Phase I and II)
- Late Stage (Phase III)
- Avelumab - Pfizer Inc.
- MPDL3280A - Roche
- MEDI4736 - AstraZeneca
- Abemaciclib - Eli Lilly and Company
Major regions analyzed under this research report are:
- North America
- Asia Pacific
- Rest of the World
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments